We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of High-Dose Methotrexate on the Outcome of Patients with Diffuse Large B-Cell Lymphoma and Skeletal Involvement.
- Authors
Mercier, Mélanie; Orvain, Corentin; Drieu La Rochelle, Laurianne; Marchand, Tony; Nunes Gomes, Christopher; Giltat, Aurélien; Paillassa, Jérôme; Clavert, Aline; Farhi, Jonathan; Rousselet, Marie-Christine; Gyan, Emmanuel; Houot, Roch; Moles-Moreau, Marie-Pierre; Hunault-Berger, Mathilde
- Abstract
Simple Summary: In this retrospective study, we analyzed the impact of adding high-dose methotrexate to standard chemotherapy on the outcome of patients with diffuse large B-cell lymphoma and skeletal involvement. Our results suggest improved outcome in those who received high-dose methotrexate which should be confirmed in prospective controlled studies. Diffuse large B-cell lymphoma (DLBCL) with extra nodal skeletal involvement is rare. It is currently unclear whether these lymphomas should be treated in the same manner as those without skeletal involvement. We retrospectively analyzed the impact of combining high-dose methotrexate (HD-MTX) with an anthracycline-based regimen and rituximab as first-line treatment in a cohort of 93 patients with DLBCL and skeletal involvement with long follow-up. Fifty patients (54%) received upfront HD-MTX for prophylaxis of CNS recurrence (high IPI score and/or epidural involvement) or because of skeletal involvement. After adjusting for age, ECOG, high LDH levels, and type of skeletal involvement, HD-MTX was associated with an improved PFS and OS (HR: 0.2, 95% CI: 0.1–0.3, p < 0.001 and HR: 0.1, 95% CI: 0.04–0.3, p < 0.001, respectively). Patients who received HD-MTX had significantly better 5-year PFS and OS (77% vs. 39%, p <0.001 and 83 vs. 58%, p < 0.001). Radiotherapy was associated with an improved 5-year PFS (74 vs. 48%, p = 0.02), whereas 5-year OS was not significantly different (79% vs. 66%, p = 0.09). A landmark analysis showed that autologous stem cell transplantation was not associated with improved PFS or OS. The combination of high-dose methotrexate and an anthracycline-based immunochemotherapy is associated with an improved outcome in patients with DLBCL and skeletal involvement and should be confirmed in prospective trials.
- Subjects
STEM cell transplantation; THERAPEUTIC use of antineoplastic agents; RITUXIMAB; PATIENT aftercare; ANTHRACYCLINES; CONFIDENCE intervals; B cell lymphoma; RETROSPECTIVE studies; METHOTREXATE; BONE tumors; CANCER patients; DISEASE relapse; DESCRIPTIVE statistics; LACTATE dehydrogenase; SURVIVAL analysis (Biometry); RADIOTHERAPY; LONGITUDINAL method
- Publication
Cancers, 2021, Vol 13, Issue 12, p2945
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers13122945